Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will FTC Challenge Product Switching In Obama Administration?

Executive Summary

Lawyers are wary that the Federal Trade Commission may take a more aggressive stance toward pharmaceutical industry practices in the Obama administration

You may also be interested in...



Evergreening Gets Trimmed? Product Switching Suits On Namenda, Others Proceeding

New York judge blocks Actavis from halting sales of Namenda IR to force switch to extended release version; Pennsylvania judge lets product hopping claims proceed against Reckitt in Suboxone antitrust litigation.

FTC’s Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban

Legislative effort on settlements kicks into high gear with Senate markup and a new bill that would rescind generic exclusivity in some cases.

Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit

The companies decide it is not worth the cost and time to battle the FTC in court; the derailed deal may signal tougher times for pharma mergers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel